Trial Profile
Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Allergan
- 13 Nov 2014 New trial record